CN111053858B - 一种含中药潞党参的健脾益生保健茶及其制备方法 - Google Patents
一种含中药潞党参的健脾益生保健茶及其制备方法 Download PDFInfo
- Publication number
- CN111053858B CN111053858B CN202010064045.0A CN202010064045A CN111053858B CN 111053858 B CN111053858 B CN 111053858B CN 202010064045 A CN202010064045 A CN 202010064045A CN 111053858 B CN111053858 B CN 111053858B
- Authority
- CN
- China
- Prior art keywords
- portions
- spleen
- tea
- group
- tonifying
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000006041 probiotic Substances 0.000 title claims abstract description 50
- 230000000529 probiotic effect Effects 0.000 title claims abstract description 50
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 50
- 241000007126 Codonopsis pilosula Species 0.000 title claims abstract description 36
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 241001122767 Theaceae Species 0.000 title claims description 89
- 239000003814 drug Substances 0.000 title claims description 32
- 235000013616 tea Nutrition 0.000 claims abstract description 92
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 50
- 239000002245 particle Substances 0.000 claims abstract description 22
- 235000019224 Camellia sinensis var Qingmao Nutrition 0.000 claims abstract description 18
- 235000020339 pu-erh tea Nutrition 0.000 claims abstract description 18
- 238000005728 strengthening Methods 0.000 claims abstract description 18
- 240000006079 Schisandra chinensis Species 0.000 claims abstract description 14
- 235000021307 Triticum Nutrition 0.000 claims abstract description 14
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 13
- 229920001353 Dextrin Polymers 0.000 claims abstract description 13
- 239000004375 Dextrin Substances 0.000 claims abstract description 13
- 240000001008 Dimocarpus longan Species 0.000 claims abstract description 13
- 235000000235 Euphoria longan Nutrition 0.000 claims abstract description 13
- 229930195725 Mannitol Natural products 0.000 claims abstract description 13
- 240000002853 Nelumbo nucifera Species 0.000 claims abstract description 13
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims abstract description 13
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims abstract description 13
- 235000006545 Ziziphus mauritiana Nutrition 0.000 claims abstract description 13
- 235000008529 Ziziphus vulgaris Nutrition 0.000 claims abstract description 13
- 235000019425 dextrin Nutrition 0.000 claims abstract description 13
- 235000010355 mannitol Nutrition 0.000 claims abstract description 13
- 239000000594 mannitol Substances 0.000 claims abstract description 13
- 241000234435 Lilium Species 0.000 claims abstract description 12
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 12
- 238000001035 drying Methods 0.000 claims abstract description 11
- 239000000203 mixture Substances 0.000 claims abstract description 10
- 244000126002 Ziziphus vulgaris Species 0.000 claims abstract description 6
- 241000675108 Citrus tangerina Species 0.000 claims abstract description 4
- 235000001188 Peltandra virginica Nutrition 0.000 claims abstract description 4
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 26
- 239000008187 granular material Substances 0.000 claims description 25
- 230000036541 health Effects 0.000 claims description 22
- 238000001914 filtration Methods 0.000 claims description 15
- 241000209140 Triticum Species 0.000 claims description 13
- 239000000843 powder Substances 0.000 claims description 13
- 238000007873 sieving Methods 0.000 claims description 12
- 244000197580 Poria cocos Species 0.000 claims description 11
- 235000008422 Schisandra chinensis Nutrition 0.000 claims description 11
- 240000000038 Ziziphus mauritiana Species 0.000 claims description 7
- 239000007779 soft material Substances 0.000 claims description 7
- 238000005303 weighing Methods 0.000 claims description 7
- 238000000605 extraction Methods 0.000 claims description 6
- 238000005469 granulation Methods 0.000 claims description 6
- 230000003179 granulation Effects 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 5
- 238000011049 filling Methods 0.000 claims description 3
- 230000001376 precipitating effect Effects 0.000 claims description 3
- 238000002791 soaking Methods 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- 210000000952 spleen Anatomy 0.000 abstract description 47
- 230000000694 effects Effects 0.000 abstract description 41
- 210000004369 blood Anatomy 0.000 abstract description 20
- 239000008280 blood Substances 0.000 abstract description 20
- 210000005036 nerve Anatomy 0.000 abstract description 11
- 230000008901 benefit Effects 0.000 abstract description 6
- 230000001914 calming effect Effects 0.000 abstract description 5
- 239000004480 active ingredient Substances 0.000 abstract description 3
- 238000009472 formulation Methods 0.000 abstract description 3
- 238000009776 industrial production Methods 0.000 abstract description 2
- 244000269722 Thea sinensis Species 0.000 abstract 3
- 244000248825 Peltandra virginica Species 0.000 abstract 1
- 244000098338 Triticum aestivum Species 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 42
- 239000000243 solution Substances 0.000 description 31
- 229940079593 drug Drugs 0.000 description 14
- 230000036039 immunity Effects 0.000 description 13
- 208000024891 symptom Diseases 0.000 description 13
- 230000001105 regulatory effect Effects 0.000 description 12
- 210000002784 stomach Anatomy 0.000 description 12
- 241000756943 Codonopsis Species 0.000 description 11
- 238000010521 absorption reaction Methods 0.000 description 11
- 206010016256 fatigue Diseases 0.000 description 11
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 10
- 102000003812 Interleukin-15 Human genes 0.000 description 10
- 108090000172 Interleukin-15 Proteins 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 230000007958 sleep Effects 0.000 description 9
- 230000007812 deficiency Effects 0.000 description 8
- 235000005911 diet Nutrition 0.000 description 8
- 230000037213 diet Effects 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 230000002708 enhancing effect Effects 0.000 description 8
- 230000002496 gastric effect Effects 0.000 description 8
- 230000001737 promoting effect Effects 0.000 description 8
- 230000002936 tranquilizing effect Effects 0.000 description 8
- 230000035622 drinking Effects 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- 230000003647 oxidation Effects 0.000 description 7
- 238000007254 oxidation reaction Methods 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 102000000588 Interleukin-2 Human genes 0.000 description 6
- 108010002350 Interleukin-2 Proteins 0.000 description 6
- 108090000978 Interleukin-4 Proteins 0.000 description 6
- 102000004889 Interleukin-6 Human genes 0.000 description 6
- 108090001005 Interleukin-6 Proteins 0.000 description 6
- 229920001491 Lentinan Polymers 0.000 description 6
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 102000019197 Superoxide Dismutase Human genes 0.000 description 6
- 108010012715 Superoxide dismutase Proteins 0.000 description 6
- 230000013872 defecation Effects 0.000 description 6
- 230000003203 everyday effect Effects 0.000 description 6
- 229940115286 lentinan Drugs 0.000 description 6
- 229940118019 malondialdehyde Drugs 0.000 description 6
- 230000000144 pharmacologic effect Effects 0.000 description 6
- 230000002633 protecting effect Effects 0.000 description 6
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 5
- 206010012735 Diarrhoea Diseases 0.000 description 5
- 108010023302 HDL Cholesterol Proteins 0.000 description 5
- 108010028554 LDL Cholesterol Proteins 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 229930003268 Vitamin C Natural products 0.000 description 5
- 230000032683 aging Effects 0.000 description 5
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000009182 swimming Effects 0.000 description 5
- 235000019154 vitamin C Nutrition 0.000 description 5
- 239000011718 vitamin C Substances 0.000 description 5
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 4
- 206010051246 Photodermatosis Diseases 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 230000002567 autonomic effect Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 102000008616 interleukin-15 receptor activity proteins Human genes 0.000 description 4
- 108040002039 interleukin-15 receptor activity proteins Proteins 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 238000000465 moulding Methods 0.000 description 4
- 230000008845 photoaging Effects 0.000 description 4
- 210000001541 thymus gland Anatomy 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 206010000060 Abdominal distension Diseases 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 3
- 208000019790 abdominal distention Diseases 0.000 description 3
- 230000036528 appetite Effects 0.000 description 3
- 235000019789 appetite Nutrition 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 230000004186 co-expression Effects 0.000 description 3
- 230000003750 conditioning effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000005176 gastrointestinal motility Effects 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 206010022437 insomnia Diseases 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 230000003340 mental effect Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 206010008479 Chest Pain Diseases 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 206010013789 Dry throat Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000002929 anti-fatigue Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 230000000994 depressogenic effect Effects 0.000 description 2
- 229960003529 diazepam Drugs 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 230000008451 emotion Effects 0.000 description 2
- 230000007661 gastrointestinal function Effects 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 229940088592 immunologic factor Drugs 0.000 description 2
- 239000000367 immunologic factor Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 235000009917 Crataegus X brevipes Nutrition 0.000 description 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 description 1
- 235000009685 Crataegus X maligna Nutrition 0.000 description 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 description 1
- 235000009486 Crataegus bullatus Nutrition 0.000 description 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 description 1
- 235000009682 Crataegus limnophila Nutrition 0.000 description 1
- 240000000171 Crataegus monogyna Species 0.000 description 1
- 235000004423 Crataegus monogyna Nutrition 0.000 description 1
- 235000002313 Crataegus paludosa Nutrition 0.000 description 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 208000027534 Emotional disease Diseases 0.000 description 1
- 240000000599 Lentinula edodes Species 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- 235000017784 Mespilus germanica Nutrition 0.000 description 1
- 244000182216 Mimusops elengi Species 0.000 description 1
- 235000000560 Mimusops elengi Nutrition 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 235000007837 Vangueria infausta Nutrition 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000001490 effect on brain Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- CDCHDCWJMGXXRH-UHFFFAOYSA-N estazolam Chemical compound C=1C(Cl)=CC=C(N2C=NN=C2CN=2)C=1C=2C1=CC=CC=C1 CDCHDCWJMGXXRH-UHFFFAOYSA-N 0.000 description 1
- 229960002336 estazolam Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- -1 flavonoid compounds Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000011575 immunodeficient mouse model Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000017971 listlessness Diseases 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000004799 sedative–hypnotic effect Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- JGVWCANSWKRBCS-UHFFFAOYSA-N tetramethylrhodamine thiocyanate Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=C(SC#N)C=C1C(O)=O JGVWCANSWKRBCS-UHFFFAOYSA-N 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/06—Treating tea before extraction; Preparations produced thereby
- A23F3/14—Tea preparations, e.g. using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/77—Sapindaceae (Soapberry family), e.g. lychee or soapberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8967—Lilium, e.g. tiger lily or Easter lily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
一种含中药潞党参的健脾益生保健茶及其制备方法,是由如下重量份数的成分组成的:潞党参15份~30份、普洱茶20份~40份、莲子10份~20份、大枣10份~15份、五味子3份~8份、浮小麦2份~5份、百合4份~10份、茯苓10份~20份、桂圆8份~12份、陈皮4份~8份、糊精6份~12份、甘露醇5份~10份、乙醇溶液8份~12份。本发明提供的一种含中药潞党参的健脾益生保健茶选自颗粒剂型,可达到健脾燥湿、益气养血、宁心安神的保健作用,颗粒大小适中,溶化性好,防潮性佳,且颗粒制剂具有冲泡时间短,各组成的有效成分含量多、适合工业化生产等优点,便于开发应用。
Description
技术领域
本发明涉及保健食品技术领域,尤其涉及一种健脾益生保健茶及其制备方法。
背景技术
饮茶是中国自古就有的生活习惯与交际礼节。近年来,茶的保健养生作用日益受到人们的重视,益生茶饮开始逐渐增多,益生茶与普通茶相比,更侧重于养生保健,被广泛应用于预防、保健、康复等诸多领域。市面上常见的益生茶主要为袋泡茶和散茶,袋泡茶相比散茶更加方便快捷,但也存在着冲泡时间长,功能成分溶解较少等缺点。
脾虚证是指因脾气虚损而引起的以脾的生理功能失常为主要表现的病理现象和病症。脾虚证大多由饮食不节、劳倦过度、年老体虚所致。李东垣《脾胃论》中诉:“百病皆有脾胃衰而生也”,可见人体疾病的发生与脾胃功能受损密切相关,且脾主运化而化生气血,脾胃功能强可滋养正气,以增强人体抗病能力。但目前市面上益生茶的功能成分普遍为菊花、枸杞和山楂等,具有清热、平肝明目、补虚益精、活血消食的功效,以健脾为主要功效的益生茶较少见,无法完全满足人们逐渐提高的养生需求。因此,寻找健康有效的健脾益生方法具有很现实的重要意义,安全有效的健脾益生活性物质一直是人们期待解决问题的关键,现在市场迫切需要开发一种有健脾益生并无毒、能被生物体完全吸收的优点的保健品。
发明内容
针对上述问题,本发明的目的是提供一种含中药潞党参的健脾益生保健茶及其制备方法。该健脾益生保健茶选自颗粒剂型,以潞党参为主要药物成分,可达到健脾燥湿、益气养血、宁心安神的保健作用,颗粒大小适中,溶化性好,防潮性佳,且颗粒制剂具有冲泡时间短,各组成的有效成分含量多、适合工业化生产等优点,便于开发应用。
为了实现上述目的,本发明采用以下技术方案。
一种含中药潞党参的健脾益生保健茶,是由如下重量份数的成分组成:
潞党参15份~30份、普洱茶20份~40份、莲子10份~20份、大枣10份~15份、五味子3份~8份、浮小麦2份~5份、百合4份~10份、茯苓10份~20份、桂圆8份~12份、陈皮4份~8份、糊精6份~12份、甘露醇5份~10份、乙醇溶液8份~12份。
一种含中药潞党参的健脾益生保健茶的制备方法,具体包括以下步骤。
步骤1、制备中药浸膏粉。
(1)称取潞党参、莲子、大枣、五味子、浮小麦、百合、茯苓、桂圆、陈皮原料并进行粉碎后,在10倍质量的水中浸泡1小时,再于100℃恒温水浴锅中提取3小时,100目过滤得提取液A和滤渣B。
(2)向步骤(1)得到的滤渣B加入8倍质量水,于100℃恒温水浴锅中提取2小时,100目过滤后得提取液C和滤渣D,将提取液A与提取液C合并得提取液E。
(3)向步骤(2)得到的滤渣D中边加入1倍质量的浓度为90%的乙醇溶液边搅拌进行醇沉,静置24小时,取上清液,减压回收乙醇至无醇味,得提取液F。
(4)将步骤(2)得到的提取液E和步骤(3)得到的提取液F合并后减压浓缩成质量浓度为75%-80%的浸膏,再将浸膏进行真空干燥后粉碎,80目过滤后得到中药浸膏粉,备用。
步骤2、普洱茶提取:向普洱茶中加入10倍质量水,于100℃恒温水浴锅中提取3次,每次提取时间为2小时,分别100目滤过得提取液,合并3次获得的提取液,减压浓缩成质量浓度为75%-80%的浸膏,再将浸膏进行真空干燥后粉碎,80目过滤后得到普洱茶提取物,备用。
步骤3、取糊精、甘露醇分别过80目筛,备用。
步骤4、将步骤(4)中的中药浸膏粉、步骤2中的普洱茶提取物、步骤3中的糊精和甘露醇均匀混合,得到成分混合物,备用。
步骤5、向步骤4得到的成分混合物中加入乙醇溶液,混合以制软材,用摇摆式颗粒机将软材过20目筛制粒,将得到的颗粒于55℃干燥4小时,再将干燥颗粒过20目筛整粒,即得到茶颗粒。
步骤6将步骤5中的茶颗粒灭菌后装入已灭菌茶袋中,即得健脾益生保健茶。
所述乙醇溶液为质量浓度85%的乙醇溶液。
一种含中药潞党参的健脾益生保健茶中各组成成分的药理作用及功效如下。
潞党参:潞党参属党参中的地道品种,味甘,性平,有健脾益肺、补中益气、养血生津作用。现代研究表明潞党参具有保护胃黏膜、调整胃肠运动功能、增强骨髓的造血功能、扩张血管、改善全身微循环、兴奋中枢神经作用、增强机体免疫的功能、抗疲劳等功效。
普洱茶:普洱茶为云南特有名茶,具有养胃护胃、调整胃肠运动功能、降压、抗动脉硬化、降血脂、抗氧化、清除自由基以及抗病毒等多种药理活性。
莲子:莲子有补脾止泻、清心安神、交通心肾、涩精止血之功能,中医常用于补脾益肾、止血镇痛、解热安神。现代研究证明莲子具有降压、调节血脂、抗癌、神经保护、抗氧化和清除自由基等多种药用价值和保健功能。
大枣:大枣味甘、性温,有补脾胃、补中益气、养血安神的作用,主要用于脾虚食少,乏力便溏之症。现代多项临床医学研究均证实,大枣具有提高机体免疫力、降血脂、抗氧化、抗衰老、保护肝脏、延缓疲劳等作用。
五味子:五味子药用价值极高,具益气生津、补肾宁心之功,有强身健体之效。现代药理学研究表明,五味子有较好的保护肝肾、镇静催眠、抗氧化、提高记忆力、提高免疫力、降糖、抗衰老、抑菌抗炎、调节胃肠平滑肌等作用。
浮小麦:《本草纲目》记载浮小麦有“益气除热、止自汗盗汗、骨蒸虚热”的功效。药理研究表明浮小麦可降低人体胆固醇及甘油三酯、提高机体免疫力、保护肝脏等作用。
百合:百合有养阴润肺、清心安神的功效。百合含有多种营养成分及总磷脂、多糖、粗纤维、酚类、皂苷等对人体有益的活性成分。研究显示百合具有抗氧化、抗衰老、抗抑郁、免疫调节、镇静安神、降血糖、止咳祛痰平喘、抗过敏等保健功能。
茯苓:茯苓可健脾健胃、宁心安神、利水渗湿。茯苓主要含三萜类和多糖类化合物,具有调节胃肠功能、利尿、抗炎、保肝、调节免疫、镇静等药理作用。
桂圆:桂圆味甘性温,有补益心脾、养血安神的功效,用于治疗思虑伤脾、头晕失眠、心悸等症。现代研究显示桂圆对脑细胞有营养作用,可改善记忆力低下、头晕失眠、疲劳、神经衰弱等。此外,还具有抑制脂质过氧化、降血脂、增强免疫、抗衰老的作用。
陈皮:陈皮具理气健脾、燥湿化痰之功效,主要含有黄酮类化合物和人体所需微量元素。陈皮提取物具有调节胃肠功能、抗氧化、提高免疫力、营养神经、抗菌、抗过敏等作用。
糊精和甘露醇是医药、食品等产品中常用的辅料,主要起粘合的作用,可改善颗粒的吸湿性和融化性,提升饮用的舒适感,同时增强健脾益生保健茶颗粒的稳定性。
乙醇溶液:作为润湿剂以制作软材,从而得到健脾益生保健茶颗粒。
本发明中的健脾益生保健茶以潞党参为君药,健脾益肺、养血生津。因脾胃气虚,运化失常,故臣以五味子、浮小麦,以补益脾胃之气;又因脾主湿,脾胃既虚,运化无力,则湿浊易于停滞,故加茯苓、陈皮共为臣药,健脾燥湿,助脾运化,使潞党参、五味子、浮小麦补而不滞。再以莲子、百合、桂圆为佐药,不仅可增强君、臣药的健脾之效,还可补充养心安神之功,强化了本组方健体养生的作用。以大枣为使药,助臣药补中益气之力,强佐药养心安神之效,更兼调和诸药,而司使药之职。诸药合力,重在补益脾胃,兼渗利湿浊,成益气健脾之功,又补充以养血安神,共同实现健脾养生的作用。从现代药理学角度看,本组方具多种养生保健功效,可起到调整胃肠运动功能、改善全身微循环、增强骨髓的造血功能、增强机体免疫的功能、镇静催眠、调节血脂、抗衰老、延缓疲劳、抗氧化和清除自由基的作用。
与现有技术相比,本发明的有益效果如下。
1)本发明提供的健脾益生保健茶,选用颗粒剂型,在制备工艺中对原料进行了提纯处理,使冲泡时能够充分有效的将原料中的有效物质溶入茶饮中,相比于一般的益生茶饮,节省了煎煮的时间,提高了有效成分的含量,更加方便人们在日常的工作生活中饮用。且颗粒剂型也更加适合大规模的生产制备。
2)本发明提供的健脾益生保健茶,以潞党参为主要药物成分,具有健脾益肺、补中益气、滋补强壮、增强人体免疫能力的功效,又加以莲子、大枣、五味子、浮小麦、百合、茯苓、桂圆、陈皮,组方合理,共同实现健脾益气、养心安神的调养保健作用。
3)本发明提供的健脾益生保健茶,选用糊精和甘露醇作为颗粒的辅料,起粘合作用,可改善颗粒的吸湿性和融化性,提升饮用的舒适感,同时增强了健脾益生保健茶颗粒的稳定性。
4)本发明提供的健脾益生保健茶,具有健脾益肺、补中益气、滋补强壮、增强人体免疫能力的功效,可实现健脾益气、养心安神的调养保健作用;颗粒大小适中,溶化性好,防潮性佳,且生产工艺简单,易于放大生产。
附图说明
图1是各组小鼠体重及脏器指数,注:与空白组比较,##P<0.05;与模型组比较,*P<0.05。
图2是各组小鼠IL-2、IL-4水平,注:与空白组比较,##P<0.01;与模型组比较,**P<0.01。
图3是各组小鼠IL-6、TNF-α、IL-15含量,注:与空白对照组比较,**P<0.01;与模型对照组比较,##P<0.01。
图4是各组小鼠IL-15与IL-15R共表达的检测结果,注:与空白对照组比较,*P<0.01;与模型对照组比较,#P<0.01;与VE组比较,△P>0.01。
图5是各组小鼠的自主活动次数和站立次数结果,注:与空白组比较,**P<0.01,##P<0.05。
图6是各组小鼠的SOD和MDA含量结果,注:与模型组比较,*P<0.05。
图7是各组小鼠的TC、TG、HDL-C、LDL-C含量结果,注:与空白组比较,**P<0.01;与模型组比较,##P<0.01。
具体实施方式
下面结合具体实施例及附图对本发明进行详细说明。
实施例1一种健脾益生保健茶的制备方法及其质量检查。
一、制备方法。
一种含中药潞党参的健脾益生保健茶,是由如下重量份数的成分组成:潞党参20份、普洱茶25份、莲子15份、大枣15份、五味子5份、浮小麦3份、百合5份、茯苓15份、桂圆10份、陈皮5份、糊精9份、甘露醇9份、乙醇溶液10份。
一种含中药潞党参的健脾益生保健茶的制备方法,具体包括以下步骤。
1.制备中药浸膏粉。
(1)称取潞党参、莲子、大枣、五味子、浮小麦、百合、茯苓、桂圆、陈皮原料并进行粉碎后,在10倍质量的水中浸泡1小时,再于100℃恒温水浴锅中提取3小时,100目过滤得提取液A和滤渣B。
(2)向步骤(1)得到的滤渣B加入8倍质量水,于100℃恒温水浴锅中提取2小时,100目过滤后得提取液C和滤渣D,将提取液A与提取液C合并得提取液E。
(3)向步骤(2)得到的滤渣D中边加入1倍质量的浓度为90%的乙醇溶液边搅拌进行醇沉,静置24小时,取上清液,减压回收乙醇至无醇味,得提取液F。
(4)将步骤(2)得到的提取液E和步骤(3)得到的提取液F合并后减压浓缩成质量浓度为75%-80%的浸膏,再将浸膏进行真空干燥后粉碎,80目过滤后得到中药浸膏粉,备用。
2.普洱茶提取:向普洱茶中加入10倍质量水,于100℃恒温水浴锅中提取3次,每次提取时间为2小时,分别100目滤过得提取液,合并3次获得的提取液,减压浓缩成质量浓度为75%-80%的浸膏,再将浸膏进行真空干燥后粉碎,80目过滤后得到普洱茶提取物,备用。
3.取糊精、甘露醇分别过80目筛,备用。
4.将步骤(4)中的中药浸膏粉、步骤2中的普洱茶提取物、步骤3中的糊精和甘露醇均匀混合,得到成分混合物,备用。
5.向步骤4得到的成分混合物中加入乙醇溶液,混合以制软材,用摇摆式颗粒机将软材过20目筛制粒,将得到的颗粒于55℃干燥4小时,再将干燥颗粒过20目筛整粒,即得到茶颗粒。
6.将步骤5中的茶颗粒灭菌后装入已灭菌茶袋中,即得健脾益生保健茶。
所述乙醇溶液为质量浓度85%的乙醇溶液。
所述潞党参、莲子、大枣、五味子、浮小麦、百合、茯苓、桂圆、陈皮购于安徽省毫州市大西北药业有限责任公司;普洱茶购于普洱市思茅区藏香茶业有限公司;糊精购于曲阜市天利药用辅料有限公司;甘露醇购于天津市北辰方正试剂厂;乙醇溶液购于河北瑞康医药科技有限公司。
二、质量检查。
1、颗粒的粒度测试。
采用双筛分法测定颗粒粒度。称取实施例1的健脾益生保健茶三份,每份约30g,分别放置在一号筛网中,下方放置五号筛网,左右往返,水平过筛,过筛时轻叩筛网3min。取无法过一号筛网和能过五号筛网的大颗粒及细粉末,精密称取其重量为A,并计算其占总重量的百分比,即粒度,结果见表1。
表1.粒度测试结果
组分 | 总质量(g) | A(g) | 粒度 |
第一份 | 30.0543 | 2.0765 | 6.91% |
第二份 | 29.9573 | 1.0324 | 3.45% |
第三份 | 30.1452 | 2.3472 | 7.79% |
由表1中实验结果可知,三份颗粒剂粒度平均值为6.05%,且三组粒度均未超过15%,说明颗粒大小符合规定。
2、颗粒的溶化性测试。
取实施例1的健脾益生保健茶三份,每份8g,分别加入200ml的热水,快速搅拌5min,立刻观察并记录结果,结果见表2。
表2.溶化性测试结果
组分 | 溶化情况 |
第一份 | 颗粒全部溶化,有轻微浑浊现象 |
第二份 | 颗粒全部溶化,有轻微浑浊现象 |
第三份 | 颗粒全部溶化,有轻微浑浊现象 |
由表2中实验结果可知,三份颗粒全部溶化,有轻微浑浊现象,说明颗粒溶化性较好,符合规定。
3、颗粒的吸湿性测试。
精密称取实施例1的健脾益生保健茶三份,每份5g,平铺在已干燥至恒重的含盖玻璃称量瓶底部,厚约2mm,精密称量后置于盛有氯化钠过饱和水溶液的透明玻璃干燥器内(打开称量瓶盖),于25℃恒温培养箱内保持48h后,取出称量瓶,将瓶盖盖好,精密称重,并计算吸湿率(吸湿率=(吸湿后重量-吸湿前重量)/吸湿前重量×100%),结果见表3。
表3.吸湿性测试结果
组分 | 吸湿前重量 | 吸湿后重量 | 吸湿率 |
第一份 | 5.0004 | 5.3249 | 6.49% |
第二份 | 5.0016 | 5.3081 | 6.13% |
第三份 | 5.0045 | 5.3187 | 6.28% |
由表3中实验结果可知,48h三份颗粒吸湿率分别为6.49%、6.13%、6.28%,说明颗粒吸湿性低,防潮性好。
实施例2本发明健脾益生保健茶药理作用研究。
1、调节免疫作用。
将40只ICR小鼠随机分为4组,分别为:空白组、模型组、香菇多糖(0.2g/kg)组、潞党参提取物(6.6g/kg)组,每组10只。除空白组外,其余各组均腹腔注射环磷酰胺50mg/kg,每天一次,连续3天建立免疫缺陷小鼠模型。造模后1天开始给药,连续14天,空白组和模型组均灌胃予生理盐水,香菇多糖组灌胃香菇多糖,潞党参提取物组灌胃实施例1中的潞党参提取物。于第14天给药后,禁食不禁水12h,称取小鼠的体重;解剖小鼠分离胸腺和脾脏,吸去表面残留血液,称重,并分别计算脏器指数(脏器指数=脏器质量/体重×100%),,结果见表4、图1;摘眼球取血分离血清采用酶联免疫吸附法(Elisa法)进行IL-2、IL-4水平检测,结果见表5、图2。
组别 | 体重(g) | 胸腺指数(%) | 脾脏指数(%) |
空白组 | 34.24±4.87 | 0.78±0.16 | 0.18±0.04 |
模型组 | 24.36±2.06<sup>##</sup> | 0.45±0.09<sup>##</sup> | 0.10±0.03<sup>##</sup> |
香菇多糖 | 30.59±3.27<sup>*</sup> | 1.32±0.14<sup>*</sup> | 0.25±0.05<sup>*</sup> |
潞党参提取物组 | 28.64±3.82<sup>*</sup> | 1.15±0.23<sup>*</sup> | 0.22±0.08<sup>*</sup> |
组别 | IL-2(pg/L) | IL-4(pg/L) |
空白组 | 150.82±21.84 | 71.72±11.28 |
模型组 | 96.36±17.62<sup>##</sup> | 41.39±7.93<sup>##</sup> |
香菇多糖 | 137.11±19.80<sup>**</sup> | 83.67±13.21<sup>**</sup> |
潞党参提取物组 | 108.25±18.46<sup>**</sup> | 74.35±11.28<sup>**</sup> |
结果显示,与空白组相比,模型组、香菇多糖组、潞党参提取物组小鼠的体重均显著下降(P<0.05),模型组小鼠的胸腺指数和脾脏指数均显著下降(P<0.05),与模型组相比,香菇多糖组和潞党参提取物组小鼠的体重、胸腺指数、脾脏指数均显著升高(P<0.05),差异具有统计学意义,表明潞党参提取物能促进免疫抑制小鼠的免疫器官发育,增强免疫能力。与空白组相比,模型组血清中的IL-2、IL-4水平均显著下降(P<0.01),与模型组相比,香菇多糖组和潞党参提取物组小鼠血清中的IL-2、IL-4水平均显著增加(P<0.01),结果具有统计学意义,表明潞党参提取物能增强免疫抑制小鼠血清中免疫因子的水平,增强免疫作用。
综上潞党参提取物能促进免疫器官发育,提高血清中免疫因子的水平,对免疫具有调节作用。
2、抗皮肤光老化作用。
将60只小鼠随机分成4组,分别是空白对照组、模型对照组、阳性对照组(VE组)和潞党参提取物组。对空白对照组采取正常饲养,对阳性对照组(VE组)、中药剂量组和模型对照组进行UV照射以完成皮肤光老化模型制备。模型对照组和空白对照组给生理盐水,潞党参提取物组给相应剂量药液,阳性对照组(VE组)给予维生素E滴剂,于造模前30min灌胃。造模完成后,采用酶联免疫吸附法(Elisa法)检测组织中IL-6、TNF-α、IL-15含量的表达水平,结果见表6、图3。采用免疫荧光双标记法检测IL-15与IL-15R共表达的水平来研究潞党参对光老化小鼠皮肤组织中炎症因子的影响,结果见表7、图4。
组别 | IL-6(pg/ml) | TNF-α(pg/ml) | IL-15(pg/ml) |
空白对照组 | 80.923±7.452 | 90.579±6.758 | 30.453±3.352 |
模型对照组 | 300.010±65.384<sup>**</sup> | 400.470±55.494<sup>**</sup> | 90.143±15.903<sup>**</sup> |
VE组 | 142.540±23.103<sup>##</sup> | 160.170±23.374<sup>##</sup> | 60.464±9.080<sup>##</sup> |
潞党参提取物组 | 120.140±16.372<sup>##</sup> | 140.360±19.199<sup>##</sup> | 55.518±7.193<sup>##</sup> |
组别 | FITC(个/视野) | TRITC(个/视野) | merge(个/视野) |
空白对照组 | 13.000±4.690 | 11.000±3.590 | 8.400±3.502 |
模型对照组 | 104.000±18.166<sup>*</sup> | 92.000±14.877<sup>*</sup> | 87.100±15.666<sup>*</sup> |
VE组 | 58.000±10.520<sup>*#</sup> | 53.000±10.044<sup>*#</sup> | 47.600±9.686<sup>*#</sup> |
潞党参提取物组 | 60.000±10.687<sup>*#△</sup> | 55.000±10.011<sup>*#△</sup> | 51.900±9.893<sup>*#△</sup> |
实验结果显示,酶联免疫吸附法中,比照空白对照组,模型对照组皮肤组织中IL-6、TNF-α、IL-15含量的表达水平显著上升(P<0.01);比照模型对照组,潞党参提取物组皮肤组织中IL-6、TNF-α、IL-15含量的表达水平显著下降(P<0.01)。免疫荧光双标记法中,IL-15和IL-15R在各个组中均有阳性表达,其中在模型组中的表达水平最高,在中药剂量组的表达水平较模型对照组中表达水平低。提示潞党参在皮肤光老化过程中具有保护作用。
3、镇静催眠作用
将30只ICR小鼠随机分为3组,分别为:空白组、地西泮(2ml/kg)组、健脾益生保健茶(6g/kg)组,每组10只。各组小鼠均以灌胃给药,空白组灌胃以生理盐水,地西泮组灌胃地西泮,健脾益生保健茶组灌胃实施例1中的健脾益生保健茶,每天1次,连续15天。将各组小鼠于末次灌胃给药30min后,分别置于自主活动记录仪中,适应环境5min后,开启自主活动记录仪,测定并观察5min内各组小鼠的自主活动次数和站立次数,结果见表8、图5。
组别 | 自主活动次数(次) | 站立次数(次) |
空白组 | 11.80±7.01 | 62.53±20.98 |
地西泮组 | 5.65±1.75<sup>**</sup> | 40.30±8.63<sup>**</sup> |
健脾益生保健茶组 | 6.45±2.65<sup>##</sup> | 41.33±8.81<sup>**</sup> |
结果显示,与空白组相比,地西泮组小鼠的自主活动次数和站立次数均明显减少(P<0.01),健脾益生保健茶组小鼠的自主活动次数减少(P<0.05),站立次数明显减少(P<0.01)差异具有统计学意义,表明健脾益生保健茶可减少小鼠的活动次数,提示健脾益生保健茶具有一定的镇静催眠作用。
4、延缓衰老作用。
将40只ICR小鼠随机分为4组,分别为:空白组、模型组、维生素C(100mg/kg)组、健脾益生保健茶(6g/kg)组,每组10只。除空白组外,其余各组均腹腔注射D-半乳糖100mg/kg造模,每天一次,空白组和模型组灌胃予生理盐水,维生素C组和健脾益生保健茶组分别灌胃维生素C和实施例1中的健脾益生保健茶,持续3周。于末次给药24h后,摘取小鼠眼球取血分离血清,使用生化分析仪测定超氧化物歧化酶(SOD)、丙二醛(MDA)的含量,结果见表9、图6。
组别 | SOD(U/mg prot) | MDA(U/mg prot) |
空白组 | 86.42±9.29 | 24.96±3.80 |
模型组 | 72.58±6.47 | 29.64±4.46 |
维生素C组 | 96.97±7.87<sup>*</sup> | 21.87±3.14<sup>*</sup> |
健脾益生保健茶组 | 84.78±7.56<sup>*</sup> | 24.93±3.78<sup>*</sup> |
结果显示,与模型组相比,维生素C组和健脾益生保健茶组的SOD含量明显升高(P<0.05),MDA含量明显下降(P<0.05),结果具有统计学意义,表明健脾益生保健茶具有抗衰老的作用。
5、调脂作用。
将30只ICR小鼠随机分为3组,分别为:空白组、模型组、健脾益生保健茶(6g/kg)组,每组10只。除空白组给予普通饲料外,其余各组均给予高脂饲料喂养4周以造模。造模后1天开始给药,连续30天,空白组和模型组均灌胃予生理盐水,健脾益生保健茶组灌胃实施例1中的健脾益生保健茶。灌胃结束后,小鼠禁食不禁水12h,摘眼球取血分离血清,使用生化分析仪测定TC、TG、HDL-C、LDL-C含量,结果见表10、图7。
结果显示,与空白组相比,模型组的TC、TG、LDL-C含量显著升高,HDL-C含量显著下降(P<0.01),与模型组相比,健脾益生保健茶组的TC、TG、LDL-C含量显著下降,HDL-C含量显著升高(P<0.01),结果具有统计学意义,提示健脾益生保健茶具有一定的调节血脂作用。
6、抗疲劳作用
将20只ICR小鼠随机分为2组,分别为:空白组、健脾益生保健茶(6g/kg)组,每组10只。健脾益生保健茶组小鼠灌胃实施例1中的健脾益生保健茶,空白组灌胃等量生理盐水,每天1次,连续灌胃7天,于末次给药后30min,小鼠尾根部束体重5%的负重物,将小鼠放入玻璃缸,当小鼠头部沉入水中10s不能浮出水面即为体力耗竭,依次测定小鼠负重游泳的时间(从开始游泳到体力耗竭的时间),结果见表11。
组别 | 负重游泳时间(s) |
空白组 | 358.00±51.98 |
健脾益生保健茶组 | 832.50±92.19 |
结果显示,与空白组相比,健脾益生保健茶组的小鼠负重游泳时间显著延长(P<0.01),结果具有统计学意义,提示健脾益生保健茶具有一定的抗疲劳作用。
实施例3临床资料。
为进一步验证本发明的使用效果,提供以下临床资料。
1、一般资料。
选择100例志愿者(要求能配合调查,调查期间不使用其他类似的产品)饮用实施例1的产品持续30天,每天服用1-2包,每包约15g。在饮用本发明产品前及饮用本发明产品30天后分别对受试者进行调查。分别以受试者在饮食情况、排便情况、睡眠情况、精神情况为评价点,分为良好、一般和较差三个评分等级,统计对每个项目评分的人数,结果见表12。
表12.评价结果
由表12可以看出,受试者在饮用本发明后,在饮食、排便、睡眠、精神方面的情况均有明显改善,可见,本发明对饮食、排便、睡眠、精神情况具有良好的改善效果。
2、典型病例。
1)病例1。
张某,男,43岁,教师。
病症:下腹部胀气,腹泻,每日排便5-6次,大便不成形20年,伴咽干胸闷,时感神疲乏力,纳差,夜寐欠佳,小便清长,舌红,苔厚白稍黄,脉细弱。心情常郁闷,气色较差。建议予健脾益生保健茶饮调理。
应用:予实施例1中健脾益生保健茶,每天早晨加开水600ml,泡30分钟后饮用,每日2包,6d为1疗程。
疗效:服用6天后,患者自觉腹胀症状明显减轻,腹泻缓解,每日排便次数减少为3次,饮食、睡眠情况均有所改善。再进1个月,患者腹胀症状已除,每日排便1-2次,大便可成形,咽干胸闷症状消失,疲劳感明显改善,饮食佳、睡眠佳,舌淡红苔薄白,脉柔和有力,气色佳,诸症改善,随访半年未见复发。2)病例2。
刘某,女,56岁,农民。
病症:入睡困难5年,5年前因情志不畅开始入睡困难,卧床2-3小时可入睡,间断服用艾司唑仑片1mg/晚治疗,症状有所缓解。近2年效果越来越差。白天时觉疲乏无力,情志抑郁,善太息,纳差,二便可,舌红苔白,脉弦。建议予健脾益生保健茶饮调理。
应用:予实施例1中健脾益生保健茶,每天早晨加开水600ml,泡30分钟后饮用,每日2包,6d为1疗程。
疗效:服用6天后,患者自觉入睡困难症状减轻,疲乏无力症状缓解,饮食情况亦有所改善。再进1个月,患者无明显入睡困难,卧床约30分钟可入睡,白天疲乏感明显减轻,饮食、情志均有所改善,无善太息症状,舌淡红苔薄白,诸症改善,随访半年未见复发。
3)病例3。
李某,男,43岁,司机。
病症:自觉脘腹胀满,食后为甚3个月,精神不振,肢体倦怠,少气懒言,面色晄白,口不知味,纳差,大便溏薄,排便3-4次/日,小便可,夜寐可,舌淡苔白,脉弱无力。建议予健脾益生保健茶饮调理。
应用:予实施例1中健脾益生保健茶,每天早晨加开水600ml,泡30分钟后饮用,每日2包,6d为1疗程。
疗效:服用6天后,患者自觉脘腹胀满、少气懒言症状缓解,疲劳感明显减轻,食欲改善。再进1个月,患者无明显脘腹胀满、少气懒言症状,无明显肢体疲劳感,饮食可,排便1-2次/日,大便可成形,夜寐佳,舌淡红苔薄白,脉柔和有力,面色红润,诸症改善,随访1年未见复发。
Claims (2)
1.一种含中药潞党参的健脾益生保健茶,其特征在于,是由如下重量份数的成分制成的:潞党参15份~30份、普洱茶20份~40份、莲子10份~20份、大枣10份~15份、五味子3份~8份、浮小麦2份~5份、百合 4份~10份、茯苓10份~20份、桂圆8份~12份、陈皮4份~8份、糊精6份~12份、甘露醇5份~10份、乙醇溶液8份~12份。
2.如权利要求1所述的一种含中药潞党参的健脾益生保健茶的制备方法,其特征在于:
步骤1、制备中药浸膏粉:
(1)称取潞党参、莲子、大枣、五味子、浮小麦、百合、茯苓、桂圆、陈皮原料并进行粉碎后,在10倍质量的水中浸泡1小时,再于100℃恒温水浴锅中提取3小时,100目过滤得提取液A和滤渣B;
(2)向步骤(1)得到的滤渣B加入8倍质量水,于100℃恒温水浴锅中提取2小时,100目过滤后得提取液C和滤渣D,将提取液A与提取液C合并得提取液E;
(3)向步骤(2)得到的滤渣D中边加入1倍质量的浓度为90%的乙醇溶液边搅拌进行醇沉,静置24小时,取上清液,减压回收乙醇至无醇味,得提取液F;
(4)将步骤(2)得到的提取液E和步骤(3)得到的提取液F合并后减压浓缩成质量浓度为75%-80%的浸膏,再将浸膏进行真空干燥后粉碎,80目过滤后得到中药浸膏粉,备用;
步骤2、普洱茶提取:向普洱茶中加入10倍质量水,于100℃恒温水浴锅中提取3次,每次提取时间为2小时,分别100目滤过得提取液,合并3次获得的提取液,减压浓缩成质量浓度为75%-80%的浸膏,再将浸膏进行真空干燥后粉碎,80目过滤后得到普洱茶提取物,备用;
步骤3、取糊精、甘露醇分别过80目筛,备用;
步骤4、将步骤(4)中的中药浸膏粉、步骤2中的普洱茶提取物、步骤3中的糊精和甘露醇均匀混合,得到成分混合物,备用;
步骤5、向步骤4得到的成分混合物中加入乙醇溶液,混合以制软材,用摇摆式颗粒机将软材过20目筛制粒,将得到的颗粒于55℃干燥4小时,再将干燥颗粒过20目筛整粒,即得到茶颗粒;
步骤6、将步骤5中的茶颗粒灭菌后装入已灭菌茶袋中,即得一种含中药潞党参的健脾益生保健茶。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010064045.0A CN111053858B (zh) | 2020-01-20 | 2020-01-20 | 一种含中药潞党参的健脾益生保健茶及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010064045.0A CN111053858B (zh) | 2020-01-20 | 2020-01-20 | 一种含中药潞党参的健脾益生保健茶及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111053858A CN111053858A (zh) | 2020-04-24 |
CN111053858B true CN111053858B (zh) | 2021-11-19 |
Family
ID=70307578
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010064045.0A Active CN111053858B (zh) | 2020-01-20 | 2020-01-20 | 一种含中药潞党参的健脾益生保健茶及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111053858B (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103719491A (zh) * | 2013-12-31 | 2014-04-16 | 青岛恒波仪器有限公司 | 一种黄精健脾润肺保健茶及其制备方法 |
CN103734428A (zh) * | 2013-12-31 | 2014-04-23 | 青岛恒波仪器有限公司 | 一种提高免疫力的女贞子保健茶及其制备方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101249227A (zh) * | 2008-04-10 | 2008-08-27 | 北京万寿通医药科技有限公司 | 一种参芪养心胶囊 |
CN104352655A (zh) * | 2014-10-20 | 2015-02-18 | 罗田县大别山龙津茶业专业合作社 | 一种茯苓茶颗粒及其制备方法 |
CN105638977A (zh) * | 2014-12-04 | 2016-06-08 | 黑龙江众生生物工程有限公司 | 一种茯苓健脾宁心代茶冲泡饮剂及其制备方法 |
CN107184857A (zh) * | 2017-07-21 | 2017-09-22 | 成都美淼生物科技有限公司 | 一种用于改善睡眠的保健品 |
CN108617824A (zh) * | 2018-03-22 | 2018-10-09 | 安徽谓博中药股份有限公司 | 一种人参蔓越莓安眠养生茶的制备方法 |
-
2020
- 2020-01-20 CN CN202010064045.0A patent/CN111053858B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103719491A (zh) * | 2013-12-31 | 2014-04-16 | 青岛恒波仪器有限公司 | 一种黄精健脾润肺保健茶及其制备方法 |
CN103734428A (zh) * | 2013-12-31 | 2014-04-23 | 青岛恒波仪器有限公司 | 一种提高免疫力的女贞子保健茶及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN111053858A (zh) | 2020-04-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106035861A (zh) | 一种具有保健功能的桦褐孔菌代用茶及其制备方法 | |
CN103007146A (zh) | 一种增强记忆力的保健营养粉 | |
CN104940645A (zh) | 一种具有美容养颜功能的铁皮石斛中药组合物及其制剂 | |
CN106177053A (zh) | 一种包含青钱柳叶和陈皮的降血糖保健组合物 | |
CN109731066A (zh) | 一种具有抗疲劳作用的中药组合物及其应用、保健食品 | |
CN116850223A (zh) | 具有调节免疫功能的黄芪扶正茶及其制备方法 | |
CN104352542A (zh) | 一种海参雪莲的组合物制剂及其制备方法 | |
CN112843174A (zh) | 一种具有补脾养心安神功能的中药组合物及制备方法以及应用 | |
CN112755138A (zh) | 一种益气健脾棒棒糖及其制备方法 | |
CN106177477A (zh) | 一种用于降血糖、降血脂和降血压的保健组合物 | |
CN104431772A (zh) | 一种润肠排毒面食制品及其制备方法 | |
CN111053858B (zh) | 一种含中药潞党参的健脾益生保健茶及其制备方法 | |
CN106177054A (zh) | 一种包含桑白皮和陈皮的降血糖保健组合物 | |
CN111298020B (zh) | 具有抗疲劳功效的中药组合物及其制备方法与应用 | |
CN104388263A (zh) | 山楂桂圆养生中药酒及制备方法 | |
CN108186966A (zh) | 一种预防或改善老年痴呆症的组合物及其应用 | |
CN101352552B (zh) | 一种促进少儿智力和生长发育的胶囊 | |
CN113632979A (zh) | 一种男女通用的四季养生饮料及其制备方法 | |
CN106343339A (zh) | 一种营养组合物及其制备方法和应用 | |
CN105535587A (zh) | 一种治疗心肾不交型心悸失眠的中药制剂及其制备方法 | |
CN105770705A (zh) | 一种治疗儿童功能消化不良的药物制剂及其用途 | |
CN106177476A (zh) | 一种包含石斛和陈皮的降血糖保健组合物 | |
CN109170052A (zh) | 一种石斛养胃保健茶及其制备方法 | |
CN105012732B (zh) | 一种用于治疗睡眠障碍综合征的中药丸剂及制备方法 | |
CN111670977B (zh) | 一种理气健脾保健茶 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |